AVDL

Avadel PharmaceuticalsNasdaqGM:AVDL Stock Report

Market Cap

US$467.6m

7D

0.1%

1Y

35.0%

Updated

16 Sep, 2021

Data

Company Financials +
AVDL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AVDL Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.

Avadel Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Avadel Pharmaceuticals
Historical stock prices
Current Share PriceUS$7.98
52 Week HighUS$4.83
52 Week LowUS$10.33
Beta1.31
1 Month Change6.26%
3 Month Change1.66%
1 Year Change35.03%
3 Year Change77.33%
5 Year Change-41.88%
Change since IPO-32.09%

Recent News & Updates

Aug 05

Avadel Pharmaceuticals, The Jazz-Killer

Avadel's once-nightly FT218 improves considerably over Xyrem's twice-nightly dosing. Jazz's recent lawsuit seems spurious, given how they lost to Amneal before. October PDUFA and current low prices make AVDL a compelling buy.

Jul 23
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Jun 09

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Avadel Pharmaceuticals ([[AVDL]]) announces new post hoc analyses of data from Phase 3 REST-ON trial of FT218. FT218 is currently under FDA review with PDUFA target date of October 15, 2021. Highlights from the poster presentations are outlined below. Efficacy of FT218 by Narcolepsy Subtype:FT218 demonstrated statistically significant improvement in excessive daytime sleepiness ((EDS)) at all evaluated doses in patients with narcolepsy subtypes 1 (NT1, with cataplexy) and 2 (NT2, without cataplexy) compared to placebo.The least squares ((LS)) mean difference in

Shareholder Returns

AVDLUS PharmaceuticalsUS Market
7D0.1%-2.6%-0.6%
1Y35.0%12.1%33.6%

Return vs Industry: AVDL exceeded the US Pharmaceuticals industry which returned 12.8% over the past year.

Return vs Market: AVDL exceeded the US Market which returned 33.7% over the past year.

Price Volatility

Is AVDL's price volatile compared to industry and market?
AVDL volatility
AVDL Beta1.31
Industry Beta0.64
Market Beta1

Stable Share Price: AVDL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: AVDL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201532Greg Divishttps://www.avadel.com

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company’s lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017.

Avadel Pharmaceuticals Fundamentals Summary

How do Avadel Pharmaceuticals's earnings and revenue compare to its market cap?
AVDL fundamental statistics
Market CapUS$467.60m
Earnings (TTM)-US$56.01m
Revenue (TTM)n/a

0x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVDL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$56.01m
Earnings-US$56.01m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.96
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio119.3%

How did AVDL perform over the long term?

See historical performance and comparison

Valuation

Is Avadel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AVDL ($7.98) is trading below our estimate of fair value ($131.01)

Significantly Below Fair Value: AVDL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AVDL is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: AVDL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVDL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AVDL is overvalued based on its PB Ratio (3.9x) compared to the US Pharmaceuticals industry average (3.3x).


Future Growth

How is Avadel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

73.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVDL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: AVDL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AVDL's is expected to become profitable in the next 3 years.

Revenue vs Market: AVDL's revenue (57.7% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: AVDL's revenue (57.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AVDL's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Avadel Pharmaceuticals performed over the past 5 years?

-26.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVDL is currently unprofitable.

Growing Profit Margin: AVDL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVDL is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.

Accelerating Growth: Unable to compare AVDL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVDL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: AVDL has a negative Return on Equity (-47.11%), as it is currently unprofitable.


Financial Health

How is Avadel Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AVDL's short term assets ($230.7M) exceed its short term liabilities ($16.3M).

Long Term Liabilities: AVDL's short term assets ($230.7M) exceed its long term liabilities ($147.4M).


Debt to Equity History and Analysis

Debt Level: AVDL's debt to equity ratio (119.3%) is considered high.

Reducing Debt: AVDL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVDL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AVDL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Avadel Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVDL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVDL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVDL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVDL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVDL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Greg Divis (54 yo)

2.67yrs

Tenure

US$3,143,694

Compensation

Mr. Gregory J. Divis Jr., also known as Greg, has been the Chief Executive Officer and Director of Avadel Pharmaceuticals plc since June 3, 2019. Mr. Divis served as an Interim Chief Executive Officer at A...


CEO Compensation Analysis

Compensation vs Market: Greg's total compensation ($USD3.14M) is above average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AVDL's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: AVDL's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Avadel Pharmaceuticals plc's employee growth, exchange listings and data sources


Key Information

  • Name: Avadel Pharmaceuticals plc
  • Ticker: AVDL
  • Exchange: NasdaqGM
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$467.598m
  • Shares outstanding: 58.60m
  • Website: https://www.avadel.com

Number of Employees


Location

  • Avadel Pharmaceuticals plc
  • 10 Earlsfort Terrace
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 22:48
End of Day Share Price2021/09/16 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.